- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00993122
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients (RBV)
Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C
Descripción general del estudio
Descripción detallada
Ribavirin Pre-Treatment Study Protocol
Introduction:
- Recurrence of hepatitis C infection and liver transplant:
Recurrence of hepatitis C after liver transplant is almost universal. After liver transplantation, the progression of chronic hepatitis C is more aggressive and an high percentage of recipients develop cirrhosis and rapid liver decompensation (1). Recent studies have shown that the long-term-survival-rate is significantly lower compared with non-HCV infected recipients (2). Other studies founded that antiviral treatment improves survival in these patients. Thus, the treatment of hepatitis C patients after LT is a priority for transplant units.
To date, the rate of sustained virologic response (SVR) in patients with recurrent hepatitis C after liver transplantation is about 20% with standard IFN and increases to 30% with pegylated IFN and Ribavirin (3). Lack in tolerability and low compliance to the antiviral therapy may represent an important limiting factor in order to improve the SVR. Severe myelosuppression is frequent in these patients, due to the additional effect of immunosuppressive therapy, being an additional reason to reduce antiviral drug dosage (3).
- Ribavirin:
Recent studies have evaluated the effects of a ribavirin priming before the standard combined antiviral therapy in immuno-competent patients with chronic hepatitis C (4-7). The conclusion of these studies may suggest that ribavirin pre-treatment may be a way to improve the SVR.
Aim of the study:
The study is a randomized un-blind multicenter project to compare the efficacy of antiviral treatment with a RBV priming vs standard antiviral treatment in patients with recurrent hepatitis C after liver transplantation.
Ribavirin pre-treatment may:
- Ameliorate therapy-compliance
- Avoid a concomitant drugs-related hematological side effects
- Modify the intra-hepatic cytokine pattern toward a better antiviral action
- Improve the SVR.
This controlled trial is not sponsored by a drug company.
Patients:
The protocol of the study needs to be approved by the local ethic committee. Patients are enrolled in the study after been informed of the purpose and protocol of treatment and need to sign a written informed consent.
Statistical analysis, sample size and randomization:
Sample size calculations were performed using EVR as the primary outcome measure. We assumed that 48 weeks intended treatment with pegylated interferon and ribavirin in transplant patients with recurrent hepatitis C induced EVR in about 60% of patients (10). In our pilot study ribavirin priming followed by 48 weeks of pegylated interferon and ribavirin obtained EVR in 92% of patients. To show an improvement of EVR from 60 to 92% , assuming an alpha level of 0.05, and 90% power ( beta =0.20) fifty patients per group are needed.
Patients will be randomized after inclusion in the study, using an opaque envelope technique to be assigned to their treatment by a predetermined sequence at the Coordinator Center. Randomization will be stratified for genotype 1 and non1 to decrease the likelihood that uneven distribution of underlying disease severity would bias the results. Randomization will occur in blocks of four.
Definitions:
The following definitions are going to be used; during the study:
- Rapid Virological Response: complete viral clearance at week 4
- Early Virologic Response: viral reduction > 2 log after 12 weeks of combined therapy.
- Complete Early Virological Response: complete viral clearance after 12 weeks of combined therapy.
- End of treatment Virologic Response: complete viral clearance at the end of the treatment period
- Sustained Virologic Response: complete viral clearance 24 weeks after the end of treatment
- Non Responder: Absence of virological response after 12 weeks
- Relapse: recurrence of viral replication after a complete clearance during treatment time or after the conclusion of it.
- Protocol of the study:
Basal Evaluation:
- Liver biopsy within the last 6 months
- Complete biochemical assessment (liver function tests, renal function, blood tests, levels of immunosuppressive therapy)
- HCV-RNA quantitative determination
Randomization: Patient are randomized to treatment A or Treatment B):
- Treatment A:
Pre-treatment:
Ribavirin is started at 600 mg/day (or 400mg/ day if < 60 kg) and increased to 10,4 mg/kg within week 2, the therapy is continued for 8 complete weeks.
Biochemical assessment is repeated at week 2, 4, 8. Samples are stored at the same times.
HCV-RNA quantitative determination is repeated at week 8. Drug reduction is allowed when hemoglobin level is below 10 g/dL though EPO administration or whenever it is considered necessary.
Combined antiviral therapy:
For 48 weeks patients are treated with Ribavirin (same dosage) and IFN alfa2b (1,5 mcg/kg/week).
Patients are followed monthly or more frequently if required. Biochemical and virological assessment is recorded at week 4, 12, 24, 48. Surveillance is performed for any collateral effects and dose adjustment or growth factor need.
Ribavirin reduction is required when hemoglobin level is below 10 g/dL though EPO use.
IFN weekly administration should be reduced when neutrophiles count is < 750 in spite of G-CSF administration.
IFN interruption is required when neutrophiles are < 500 or platelets are < 35000.
- Treatment B:
For 48 weeks patients are treated with Ribavirin (10 mg/kg ) and pegylated IFN alfa2b weekly.
Ribavirin is started at 600 mg/day and increased to 10 mg/kg within week 2. Pegylated IFN alfa2b is administered weekly at a dose of 1,5/kg/week. Patients are followed twice monthly in the first month and at least monthly thereafter (more frequently whenever is required).
Biochemical and virological assessment is recorded at week 4, 12, 24, 48. Surveillance is performed for any collateral effects and dose adjustment or growth factor need.
Ribavirin reduction is required when hemoglobin level is below 10 g/dL though EPO use.
IFN weekly administration should be reduced when neutrophiles count is < 750 in spite of G-CSF administration.
IFN interruption is required when neutrophiles are < 500 or platelets are < 35000.
End-points of the study:
- Rapid Virological Response ( week 4)
- Early Virological Response (week 12)
- Complete Early Virological Response (week 12)
- End of treatment Virological Response (week 48)
- End of treatment Biochemical Response (week 48)
- Sustained Virological Response (Six months after the end of therapy)
Collateral effects, dose adjustment and use of growth factors are recorded.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Rome, Italia, 00100
- Sapienza University of Rome
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Liver transplantation from > 6 months
- Positive HCV-RNA viremia
- Elevated transaminase levels (greater than 1,2 normal values) in at least two consecutive determinations during the last month
- Histology pattern showing hepatitis C recurrence
Exclusion Criteria:
- Multiple organ transplantation
- Histology showing evidence of hepatic allograft rejection > 3/9 RAI score
- Concomitant active biliary disease
- Concomitant HBV infection
- Normal transaminases levels
- Less than 1500 neutrophiles in more than one blood test
- Less than 50000 platelets in more than one blood test
- Hemoglobin < 9 g/ dL
- Creatinine clearance < 35 ml/min
- Positive antibodies > 1:80
- Auto-immune thyroid pathology
- Severe psychiatric disease
- Diagnosis of ischemic cardiopathy in the last 12 months
- Active alcohol abuse
- Low compliance to other medical treatments
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: ribavirin pre-treatment
patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
|
patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
Otros nombres:
|
Comparador activo: combined stardard therapy
patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
|
patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
HCV-RNA level, Transaminases level
Periodo de tiempo: 4°,12°,24°,36°48° week and six months after therapy conclusion
|
4°,12°,24°,36°48° week and six months after therapy conclusion
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
liver biopsy and Transient elastography at baseline and after six month since therapy conclusion
Periodo de tiempo: 0°, 72° week
|
0°, 72° week
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl. 2009 Feb;15(2):126-35. doi: 10.1002/lt.21694.
- Furusyo N, Kubo N, Toyoda K, Takeoka H, Nabeshima S, Murata M, Nakamuta M, Hayashi J. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Res. 2005 Jul;67(1):46-54. doi: 10.1016/j.antiviral.2005.04.001.
- Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, Schweigler LM, Theodore D, Zacks SL, Liang TJ, Fried MW. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology. 2007 Nov;46(5):1548-63. doi: 10.1002/hep.21853.
- Ogawa K, Hige S, Nakanishi M, Yamamoto Y, Chuma M, Nagasaka A, Asaka M. Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C. Antivir Ther. 2009;14(4):513-22.
- Tox U, Schulte S, Heindl B, Goeser T, Drebber U, Stelzer A, Steffen HM. Ribavirin priming in patients with chronic hepatitis C and normal ALT: a pilot study. Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1666-70.
- Cuevas JM, Gonzalez-Candelas F, Moya A, Sanjuan R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J Virol. 2009 Jun;83(11):5760-4. doi: 10.1128/JVI.00201-09. Epub 2009 Mar 25.
- Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006 Apr;63(7-8):832-42. doi: 10.1007/s00018-005-5455-y.
- Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008 Aug;49(2):274-87. doi: 10.1016/j.jhep.2008.05.002. Epub 2008 May 22.
- Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueno MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000 Oct;32(4 Pt 1):852-8. doi: 10.1053/jhep.2000.17924.
- Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol. 2001 Nov;35(5):666-78. doi: 10.1016/s0168-8278(01)00179-9. No abstract available.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Hepatitis
- Hepatitis A
- Hepatitis C
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Antimetabolitos
- Ribavirina
Otros números de identificación del estudio
- Ribavirin Pre-treatment
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Hepatitis C
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC)Estados Unidos, Australia, Canadá, Francia, Alemania, Nueva Zelanda, Puerto Rico, España, Reino Unido
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C Genotipo 1 | Hepatitis C (VHC) | Infección viral de la hepatitis CEstados Unidos, Nueva Zelanda
-
Trek Therapeutics, PBCTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 4 | Infección viral de la hepatitis CEstados Unidos
-
AbbVieTerminadoVirus de la hepatitis C | Virus de la hepatitis C crónica
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos
-
AbbVieTerminadoHepatitis C Crónica | Hepatitis C (VHC) | Hepatitis C Genotipo 1a
-
Humanity and Health Research CentreBeijing 302 HospitalTerminadoInfección crónica por hepatitis CPorcelana
-
University Health Network, TorontoTerminadoInfección crónica por hepatitis CCanadá
-
AbbVie (prior sponsor, Abbott)TerminadoHepatitis C | Infección crónica por hepatitis C | VHC | Hepatitis C Genotipo 1Estados Unidos, Puerto Rico
Ensayos clínicos sobre ribavirin pre-treatment
-
University of OklahomaTerminadoAumento de peso | Trastorno de alimentación Neonatal | Lactante de muy bajo peso al nacerEstados Unidos
-
Sheba Medical CenterDesconocidoEnfermedad cardíaca valvular
-
Gaziosmanpasa Research and Education HospitalReclutamientoProlapso genital, no especificadoPavo
-
Humanitas Clinical and Research CenterMarco Klinger; Marta Scorsetti; Davide Franceschini; Emanuela MorenghiTerminadoMamoplastia | Radioterapia; Complicaciones | Fracaso del trasplante | Implante de seno; ComplicacionesItalia
-
Sengkang General HospitalDesconocidoFragilidad | Síndrome de FragilidadSingapur
-
Boston Medical CenterNortheastern UniversityTerminadoDepresión | Dolor crónico | Enfermedad crónica | Depresión comórbidaEstados Unidos
-
Albert Einstein Healthcare NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... y otros colaboradoresTerminadoLesión cerebral traumáticaEstados Unidos
-
John MascarenhasNational Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...TerminadoMielofibrosis primaria | Trombocitemia Post Esencial Mielofibrosis | Post Policitemia Vera MielofibrosisEstados Unidos, Canadá, Reino Unido
-
Josep M GrinyoCarlos III Health InstituteTerminadoTrastorno relacionado con el trasplante renalEspaña
-
Göteborg UniversityTerminadoCáncer de esófagoSuecia